StemCell Therapy

The 65 rating InvestorsObserver gives to Amicus Therapeutics, Inc. (FOLD) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 84 percent of stocks in the Biotechnology industry, FOLDs 65 overall rating means the stock scores better than 65 percent of all stocks.

Click Here to get the full Stock Score Report on Amicus Therapeutics, Inc. (FOLD) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 65 means the stock is more attractive than 65 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Amicus Therapeutics, Inc. (FOLD) stock is higher by 0.43% while the S&P 500 has fallen -0.36% as of 9:57 AM on Tuesday, Jan 7. FOLD is higher by $0.04 from the previous closing price of $9.38 on volume of 169,512 shares. Over the past year the S&P 500 is up 26.86% while FOLD has fallen -14.05%. FOLD lost -$1.57 per share the over the last 12 months.

To screen for more stocks like FOLD click here.

Original post:
Is Amicus Therapeutics, Inc. (FOLD) Stock a Good Buy in Biotechnology - InvestorsObserver

This entry was posted on January 10, 2020 at 9:51 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |